Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10156579 | International Journal of Radiation Oncology*Biology*Physics | 2018 | 7 Pages |
Abstract
CTC monitoring after SBRT for presumed early stage NSCLC may give lead-time notice of disease recurrence or progression. Conversely, negative CTC counts after treatment may provide reassurance of disease control. CTC analysis is thus potentially useful in enhancing clinical diagnosis and follow-up in this population.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Melissa A. MD, Gary D. MD, Louise MS, Chimbu BA, Samuel MD, Abigail T. MD, MSCE, William P. MD, Keith A. MD, PhD, Cristina MD, Stephen M. MD, Jay F. MD, PhD, Charles B. MD,